Updated 26m ago · Health
FDA Adds Rare Vision-Loss Warning to GLP-1 Drugs
The FDA on Monday ordered makers of GLP-1 drugs to warn of a potential increased risk of NAION. The condition is a rare optic nerve disorder that can cause sudden blindness.
- The rule covers Ozempic, Wegovy, Mounjaro, Zepbound and older GLP-1 diabetes drugs.
- NAION cases have been reported for every GLP-1 drug now on the market.
- FDA scientists could not identify how the drugs might raise the risk.
- 1 in 10,000 semaglutide users may develop NAION, the EMA estimated.
Why it matters: About 15% of U.S. adults, roughly 40 million people, have used a weight loss drug. The FDA now says patients and caregivers should know about the vision risk.
- NAION damage is often permanent, and no known treatment exists.
- Diabetes, sleep apnea and hypertension raise NAION risk and are common among GLP-1 users.
How 32 sources split on this story
Source landscape
Factuality
High
Mixed
Low
Strong LeftLeftLean LeftCenterLean RightRightStrong Right
Political Bias
Coverage by lean
32 sources · 40 articles · 50% Center coverage
Where they split: Coverage differs on whether to stress how rare the condition is or how severe the risk increase and personal harm are.
Center16 sources
PennLive1hOzempic, Wegovy and Zepbound get new FDA warning over rare conditionUSA Today18hDo Ozempic, Zepbound cause vision loss? New FDA warning explainedAssociated Press20hFDA adds rare vision-loss warning to popular GLP-1 drugsCNBC8hFDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, ZepboundIBTimes3hThe FDA Ordered GLP-1 Vision-Loss Warnings For Some Products. Shares of Eli Lilly and Novo Nordisk Were Unfazed.KSAT 12 San Antonio20hFDA adds rare vision-loss warning to popular GLP-1 drugsMarketWatch22hOzempic, Zepbound and other GLP-1 drugs have a possible risk of vision lossNews4Jax16hFDA adds rare vision-loss warning to popular GLP-1 drugsSky News16hFDA orders blindness risk warning on weight loss drugsThe Dallas Morning News19hFDA adds rare vision-loss warning to popular GLP-1 drugsThe Hill18hFDA warns of rare ‘eye stroke’ risk from GLP-1 drugsWFLA News Channel 818hFDA adds rare vision-loss warning to popular GLP-1 drugsWGAL 819hFDA adds warning about rare vision loss to popular GLP-1sWKBN Youngstown19hFDA adds rare vision-loss warning to popular GLP-1 drugsWPLG Local 1018hFDA adds rare vision-loss warning to popular GLP-1 drugsWPXI Pittsburgh20hFDA adds rare vision-loss warning to popular GLP-1 drugs
Left coverage, 9 sources: The left frames it as a regulatory step, noting the condition is rare and the evidence base behind the decision.
NBC News22hFDA orders new warning on GLP-1s over rare eye condition linked to sudden blindnessCNN23hUS FDA orders new eye risk warnings for Ozempic, ZepboundThe Independent34mFDA adds rare blindness warning to popular GLP-1 drugsCBS News16hGLP-1 drugs, popular for weight loss, get FDA warning of rare vision-loss side effectCleveland.com1hOzempic, Wegovy and Zepbound get new FDA warning over rare conditionGizmodo18hFDA Orders New Vision Loss Warning for Ozempic and Other GLP-1sThe Boston Globe19hFDA adds rare vision-loss warning to popular GLP-1 drugsThe Guardian3hPharma firms’ focus on weight-loss drugs could put insulin supply at risk, experts warnThe Washington Post19hFDA tells GLP-1 makers to warn of potential vision loss side effect
Right coverage, 7 sources: The right frames it around the blindness risk to users and the patients now suing the drugmakers.
Daily Mail23hFDA issues new warning for Ozempic saying it can cause blindness with 'eye stroke' side effectThe Washington Times2hFDA warning: Ozempic, other weight-loss drugs can cause vision lossNew York Post19hGLP-1 drugs must have new warning label over incurable blindness condition, says FDANTD11hFDA Issues Eye Risk Warnings for Popular GLP-1 DrugsThe Epoch Times2dFDA Mandates New Eye Risk Warning on GLP-1 DrugsTownhall21hFDA Now Requiring GLP-1 Makers to Warn About Rare but Severe Eye ConditionZeroHedge14h"Consider Discontinuing": FDA Slaps "Eye Stroke" Warning On All GLP-1 Weight-Loss Drugs
What’s next: Drugmakers must add NAION to the warnings and precautions sections of their labels.
- Nearly 100 lawsuits have been filed against Novo Nordisk since 2025, with fewer against Eli Lilly.
- How common is NAION among people taking GLP-1 drugs?
- Is the risk caused by the drugs or by the conditions their users already have?
View all